Atlas Trials

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Clinical trial NCT02977468 · UNKNOWN

Trial details

NCT number
NCT02977468
Sponsor
Eileen Connolly
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2017-10-25
Primary completion
2024-12-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.